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A hallmark of autoimmunity is the breakdown of tolerance and generation of effector 
responses against self-antigens. Re-establishment of tolerance in autoimmune 
disorders was always the most desired treatment option; however, despite many efforts, 
clinical trials have been largely unsuccessful. This also applies to the generation of 
oral tolerance, which seems to be a default response type of the mucosa-associated 
lymphoid tissues to harmless antigens. In this study, we report improved efficacy of 
oral tolerance induction by coupling antigen with the newly identified mucosal carrier 
peptide 13C. Antigen coupled to 13C is efficiently taken up in the gastrointestinal tract 
and could be visualized in cells of the lamina propria. Oral, rectal, or nasal treatment 
effectively induced the proliferation of antigen-specific T cells with some increase in the 
frequency of regulatory T cells. In a model of delayed-type hypersensitivity, especially 
intrarectal tolerization treatment resulted in reduced footpad swelling, demonstrating a 
moderate tolerogenic effect of mucosal treatment with 13C coupled antigen. Coupling of 
antigens to a transmucosal carrier, therefore, is a promising tool to improve the efficacy 
of vaccination via mucosal surfaces.
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inTrODUcTiOn
Mucosal surfaces are constantly exposed to the external environment and are main entry sites for 
pathogens. The gut mucosa discriminates between pathogens on the one side and harmless food 
antigens and commensals on the other side, with antigens from the latter categories rather eliciting 
ignorance or active tolerance in the immune system than inducing effector mechanism.
Whether a foreign antigen induces immunity or tolerance is determined by intrinsic and condi-
tional factors: the recognition of antigen or its carrier by receptors of the innate immune system, such 
as toll-like receptors, determines the outcome of the response. Conditions where inflammatory signals 
are abundant, either in the environment or on purpose by vaccine adjuvants, lead to the generation 
of strong effector responses. In contrast, antigens that do not stimulate the innate system, such as 
soluble antigens or peptides, appear to elicit induction of tolerance as a default response. Notably, 
oral administration of soluble antigens has been shown to induce systemic unresponsiveness and 
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can be mediated by the induction of regulatory cells or by clonal 
deletion and/or induction of anergy in effector cells, a response 
designated as oral tolerance (1, 2).
Manipulation of induction of oral tolerance is seen as an 
attractive means to induce antigen-specific tolerance to prevent 
autoimmune diseases. However, to date, clinical trials have 
largely been unsuccessful (3). This might depend on two major 
issues: first, pro-inflammatory conditions, prevalent in patients 
affected with autoimmune disease might suppress successful 
establishment of tolerance. It appears conceivable, however, 
that concomitant inhibition of inflammatory pathways might 
overcome this issue in future approaches. Second, vaccination 
via the oral route is of poor efficacy due to poor uptake and 
rapid degradation of antigen in the gastrointestinal tract, in 
particular when peptides are used. In the present study, we 
investigated if coupling of antigenic peptides to a specific 
cyclic peptide, which facilitates transportation through the gut 
epithelium, promotes selective uptake, and thereby induction 
of tolerance.
We recently identified the 13C peptide that increases uptake 
and transcytosis of peptides and proteins upon mucosal admin-
istration (4). The study demonstrated that labeled 13C peptide as 
well as peptide or protein bound to it is rapidly taken up by subsets 
of epithelial cells in the intestinal mucosa. These cells display the 
morphology of goblet cells which already have been implicated 
in the spontaneous uptake of antigens (5, 6). The constructs were 
then either transported into lymph and subsequently into sys-
temic circulation, or taken up by CD11c-positive cells, most likely 
dendritic cells (DCs), of the lamina propria and Peyer’s patches. 
The 13C peptide, therefore, is considered a promising candidate 
for the delivery of antigens to the immune compartment for the 
induction of tolerance via the intestinal route.
In the present work, we assessed the tolerogenic potential 
of mucosal vaccinations using 13C peptide-coupled ovalbumin 
peptide (OVA323-339: pOVA) and tested T cell responses in the 
DO11.10 transfer model system (7). Antigen-induced prolifera-
tion, induction of Foxp3+ Tregs, production of IL-10, TNF, 
and other cytokines was analyzed in reactive T cells, and the 
impact of mucosal vaccination in a delayed-type hypersensitiv-
ity (DTH) reaction was measured to detect dominant tolerance. 
We found that oral, rectal, and intranasal administration of 
13C-pOVA peptide significantly increased proliferation of 
antigen-specific T cells. Increased frequencies of regulatory T 
cells as well as a shift of the ratio of IL-10 to TNF in favor of 
IL-10 was observed in some conditions. Especially intrarectal 
application of 13C coupled to pOVA resulted in a reduced 
footpad swelling in the DTH model. Thus, the use of the 
described targeting approach might be useful to improve oral 
tolerization protocols.
MaTerials anD MeThODs
Mice
Female Balb/c mice were purchased from Charles River (Sulzfeld, 
Germany) and used at 8–10 weeks of age. DO11.10 pOVA-TCR 
transgenic mice extensively backcrossed (>10 generations) 
onto Balb/c background were housed in the DRFZ breeding 
facility. All mice were maintained under specific pathogen-free 
conditions according to national and institutional guidelines. All 
experiments were approved by Landesamt für Gesundheit und 
Soziales (LAGeSo; G0014/14).
Peptide synthesis
OVA peptide 323–339 (pOVA: ISQAVHAAHAEINEAGR), 13C- 
pOVA peptide (CTANSSAQC-βAla-ISQAVHAAHAEINEAGR), 
and 13Csc-pOVA-peptide (scrambled control; CSNAQATSC-
βAla-ISQAVHAAHAEINEAGR) were synthesized in house 
(Institute for Medical Immunology, Charité Universitätsmedizin 
Berlin, Germany) as described previously. 13C-FITC and 13Csc-
FITC were synthesized by jpt peptides (Berlin, Germany). All 
13C or 13Csc constructs were cyclysed using 10% DMSO (v/v) 
in H2O with a pH 8–8.5.
cell Preparation
Single cell suspensions were prepared from lymph nodes 
and spleen. Red blood cells were lysed in lysis buffer [0.01  M 
KHCO3; 0.155  M NH4Cl, 0.1  mM ethylenediaminetetraacetic 
acid (EDTA)] and washed with phosphate buffered saline (PBS) 
containing 0.2% BSA. CD4+ T cells were enriched using anti-CD4 
microbeads (clone: RM4-5, Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to manufacturer’s instructions and sorted 
using an AutoMACS Pro (Miltenyi Biotec). Cell enrichment 
was verified by flow cytometric analysis; a frequency of >94% 
CD4+ cells was considered successful. Generally, the frequency 
of pOVA-specific cells (KJ1.26+) was between 70–80% within the 
CD4+ cell pool.
In Vitro Proliferation assay
For in vitro analysis, CD4+ cells from DO11.10 mice were labeled 
with 1 μM CFSE in PBS. The CD4-negative fraction was depleted 
from the remaining T cells using anti-CD90 microbeads (Miltenyi 
Biotec) and AutoMACS separation and used as antigen-present-
ing cells (APCs). APCs were irradiated (30 Gy for 28 min) and 
cultured with CD4+ cells in a final concentration of 2 × 106 cells/
ml cRPMI [RPMI 1640 Glutamax medium (Gibco, Paisley, UK) 
supplemented with 10% fetal calf serum, penicillin (100 U/ml), 
streptomycin (100 μg/ml), 2-mercaptoethanol (1 mM), sodium 
pyruvate (1  mM), and HEPES (N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid; 25 mM)] with a ratio of 4:1 in 96-well 
round-bottom plates. pOVA constructs were added in various 
concentrations as indicated. Cells were incubated for 4  days 
at 37°C in a humidified 5% CO2 atmosphere. For analysis of 
proliferation, cells were stained and analyzed by flow cytometry 
by gating on pOVA-TCR+ CD4+ cells and calculating the geo-
metrical mean of the fluorescence intensity (GMFI) of the CFSE 
signal. Fold CFSE dilution was determined [fold CFSE dilution: 
GMFI (PBS control)/GMFI (sample)].
In Vivo Proliferation assay
Purified total CD4+ CFSE-labeled cells isolated from peripheral 
lymph nodes and spleens of DO11.10 mice were adoptively 
transferred i.v. into Balb/c mice (5 ×  106 cells/mouse). On the 
following day, mice were treated with peptide-pOVA constructs 
(pOVA, 13C-pOVA or13Csc-pOVA) or PBS, either i.v., orally, 
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rectally or nasally as indicated. For oral treatment, mice were fed 
intragastral with 0.5 mg peptide or equimolar amounts of peptide 
conjugates in 200 μl PBS using a feeding needle (FST, Heidelberg, 
Germany). For rectal treatment, mice were injected rectally with 
0.5 mg pOVA or equimolar amounts of peptide-conjugates (unless 
otherwise indicated) in 200 μl PBS using an umbilical catheter 
with a 0.5  mm ×  0.8  mm diameter. For nasal treatment, mice 
were anesthetized with 100 μl Dexdomitor (0.4  mg/ml, Pfizer, 
New York, NY, USA) and short isoflourane (Abbott, Chicago, IL, 
USA) inhalation. After intranasal application of 0.05 mg pOVA or 
equimolar amounts of peptide conjugates in 20 μl PBS, mice were 
injected with 100 μl Antisedan (2 mg/ml, Pfizer).
DTh reaction
Balb/c mice received a transfer of CD4+ cells from DO11.10 
donor mice and were tolerized intrarectally as described before in 
the in vivo proliferation assay. On day 8 after cell transfer, the mice 
received a subcutaneous (tailbase) injection of pOVA (125 μg) in 
complete Freund’s adjuvans [complete Freund’s adjuvant (CFA); 
Sigma-Aldrich, St. Louis, MO, USA]. To induce a strong DTH 
reaction on day 22, the mice were injected into the right footpad 
with 250  ng of pOVA in 5 μl of incomplete Freund’s adjuvans 
[incomplete Freund’s adjuvant (IFA), Sigma-Aldrich]. PBS/IFA 
emulsion was injected into the left footpad as a control. The foot-
pad swelling was determined 24 h after challenge using an Oditest 
micrometer gauge (Kroeplin Längenmesstechnik, Schlüchtern, 
Germany).
antibodies and Flow cytometry
The following antibodies and reagents were obtained from 
eBioscience (San Diego, CA, USA): eFlour 450-conjugated anti-
CD4 (RM4-5), PE conjugated anti-IL-10 (JES5-16E3) PE-Cy7 
conjugated anti-IFNγ (XMG1.2), PerCP-eFlour 710 conjugated 
anti-TNFα (MP6-XT22), eFlour 450-conjugated anti-Foxp3 
(FJK-16s), and appropriate isotype controls. V500-conjugated 
anti-CD4 (RM4-5) antibody was purchased from BD Bioscience 
(Heidelberg, Germany). Cy5-conjugated anti-pOVA-TCR 
antibody (KJ1.26) and anti-Fcγ-receptor antibody (2.4G2) were 
produced in house (Deutsches Rheuma-Forschungszentrum 
Berlin). Total rat IgG was purchased from Dianova (Hamburg, 
Germany).
Cell surface staining of lymphocytes was performed in the 
presence of anti-Fcγ-receptor antibody (20 μg/ml). Intracellular 
Forkhead-box-protein 3 (Foxp3) staining was performed using 
the anti-mouse Foxp3 staining set (eBioscience, San Diego, CA, 
USA) according to manufacturer’s instructions.
For cytokine staining, cells were stimulated with phorbol-
12-myristate 13-acetate (PMA 10 ng/ml) and ionomycin (500 ng/
ml) (Sigma-Aldrich) for 2  h at 37°C in a humidified 5% CO2 
atmosphere. Brefeldin A (10 μg/ml) (Sigma-Aldrich) was added, 
and cells were incubated for another 2 h. After surface staining, 
cells were fixed by incubation with 2% paraformaldehyde (PFA). 
Intracellular staining was performed in PBS containing 0.5% 
saponin (Sigma-Aldrich) after 5 min pre-incubation with block-
ing rat IgG. Flow cytometry was performed using a FACS Canto 
II (BD Bioscience) and analyzed with Flow Jo software (TreeStar, 
Ashland, OR, USA).
Microscopical analysis
For visualization of peptide uptake, BALB/c mice were anes-
thetized by intraperitoneal (i.p.) injection of Ketamin/Xylazin 
solution (200 and 10  mg/kg, respectively; Ketavet®, Zoetis, 
Berlin, Germany; Rompun®, Bayer, Leverkusen, Germany) and 
fluorescein isothiocyanate (FITC) coupled peptide construct 
were injected into a ligated loop of the large intestine (0.02 μg/μl). 
A 1.5-cm loop was injected with approximately 100  μl. After 
10 min incubation, the tissue was removed and fixed in 2% PFA 
solution for approximately 16 h. For dehydration, the tissue was 
incubated in increasing solutions of sucrose (10, 20, and 30%), for 
2 days at 4°C. After tissue embedding and freezing, 7 μm cryostat 
sections were made using the HM 560 Cryotom (Thermo Fischer 
Scientific, Waltham, MA, USA). Slides were frozen at −20°C until 
further use.
For immunohistochemistry, the slides were rehydrated in PBS. 
Washing steps were performed using PBS containing 1% BSA and 
0.1% Tween20. The blocking buffer additionally contained 10% 
rat serum. After incubation with blocking buffer, the sections were 
stained with anti-CD11c mAb (clone N418; produced in-house) 
conjugated to AlexaFlour®647 and washed twice. Immediately 
before analysis, the slides were mounted with DAKO mounting 
medium containing DAPI (4,6-diamino-2-phenylindole; Sigma-
Aldrich). The slides were analyzed using a LSM 710 confocal 
microscope (Carl Zeiss, Jena, Germany), and pictures were taken 
with the software Zen 2011 (Carl Zeiss MicroImaging GmbH, 
Göttingen, Germany).
For histopathological analysis in the DTH mouse model, paws 
were fixed in formalin, bone material was decalcified employing 
0.5 M EDTA pH8 and whole paws were embedded in paraffin. 
Paraffin sections were cut (1–2 μm), dewaxed, and stained his-
tochemically with hematoxylin and eosin (H&E) for overview. 
H&E stained sections were evaluated for epidermal changes 
like immune cell infiltration, spongiosis, and scurf as well as for 
inflammation of the dermis.
statistics
Data were analyzed using Prism 5 (GraphPad, La Jolla, CA, 
USA). Statistical tests include: Mann–Whitney test, followed by 
Holm–Bonferroni correction for multiple comparisons, multiple 
comparison analysis using Kolmogorov–Smirnov and D’Agostino 
and Pearson omnibus test, non-parametric Kruskal–Wallis test 
followed by Dunn’s post test and One-way ANOVA followed by 
Tukey’s or Bonferroni’s post test. Statistical analysis of cell prolif-
eration was calculated using the fold-change values. Differences 
were considered as statistically significant with p ≤ 0.05 (*), very 
significant with p  ≤  0.01 (**) and extremely significant with 
p ≤ 0.001 (***) or marked as non-significant (n.s.).
resUlTs
coupling of 13c to pOVa Peptide Does 
not alter its recognition In Vitro and 
In Vivo
An in vitro proliferation assay was employed to verify that modi-
fication of pOVA by conjugation to the cyclic 13C peptide does 
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not impair presentation by APCs and recognition by antigen-
specific T cells. pOVA or equimolar amounts of 13C-pOVA were 
tested in a 4-day culture of APCs (CD4-CD90-) and carboxyfluo-
rescein succinimidyl ester (CFSE)-labeled pOVA-specific CD4+ 
T cells from DO11.10 mice. The gating strategy is available in 
Supplementary Material (Figures S1A,B in Supplementary 
Material). We found that T cell proliferation and dose response 
curves were similar for pOVA and 13C-pOVA (Figure S2A in 
Supplementary Material). Coupling of 13C to pOVA, therefore, 
did not change the capacity of the model antigen for T cell acti-
vation. This was also verified in in  vivo experiments. One day 
prior to the peptide treatment, CD4+ cells from DO11.10 donor 
mice were adoptively transferred into Balb/c mice. Intravenous 
(i.v.) injection of 5  μg (2.8  nmol) pOVA, equimolar amounts 
of 13C-pOVA, or of a control peptide with a scrambled amino 
acid sequence coupled with pOVA (13Csc-pOVA) led to similar 
levels of T cell proliferation in the spleen, further confirming that 
pOVA is fully functional when conjugated to either 13C or 13Csc 
(Figure S2B in Supplementary Material).
Mucosal administration of 13c-pOVa 
leads to increased Proliferation of 
antigen-specific cells
To assess whether coupling of 13C to pOVA improves T cell 
responses upon administration via different mucosal routes, 
Balb/c mice adoptively transferred with CFSE-labeled pOVA-
TCR+CD4+ T cells received pOVA or equimolar amounts of pep-
tide conjugates by mucosal application. We found that mucosal 
application of 13C-pOVA resulted in significantly enhanced T 
cell proliferation when compared to pOVA. To assess whether 
the facilitated transport is restricted to distinct tissues, we applied 
the conjugates intragastrically (“oral”), rectally, and nasally. 
The proliferation of antigen-specific T cells was increased after 
treatment with 13C-pOVA compared to pOVA alone (Figure 1), 
albeit the effect differed in strength and occurrence among the 
immune tissues and delivery routes tested. Intranasal application 
of 13C-pOVA induced the highest responses overall, with signifi-
cantly higher proliferation in all three analyzed organs, medias-
tinal (MedLN) and mesenteric lymph nodes (MLN), and spleen, 
compared to the PBS-treated group (Figure 1C). Similarly, oral 
application of 13C-pOVA significantly increased proliferation in 
the MLN as well as in subcutaneous LN (SLN; pooled axillary, bra-
chial, and inguinal LN) compared to PBS treatment (Figure 1B). 
Rectal application of 13C-pOVA increased the proliferation 
especially in the MLN (Figure 1D). We conclude that the use of 
the 13C peptide as transporter module results in an increase of 
in vivo T cell responses to peptide antigen administered via the 
oral, rectal, and nasal route.
The antigen-specific T cell response was evaluated in greater 
detail after intrarectal treatment with pOVA and conjugates of 
13C and 13Csc with pOVA. A dose-dependent increase in pro-
liferation was seen for 13C-pOVA which was significantly higher 
than for pOVA or 13Csc-pOVA, the scrambled control peptide 
(Figure 2).
To visualize the uptake efficiencies in the large intestine, 13C 
and 13Csc peptides were coupled with FITC and introduced 
into a ligated loop of the colon (colon ascendens/colon trans-
versum). 13C-FITC was efficiently transported into cells of 
the lamina propria of the large intestine, already 10  min after 
injection (Figures  3A,D–F). In contrast, the control conjugate 
13Csc-FITC could not be observed in the tissue (Figures 3C,D). 
Immunofluorescence analyses revealed that epithelial cells had 
taken up 13C-FITC, but also some of the subjacent CD11c-
positive cells in the lamina propria as well as in isolated lymphoid 
follicles.
Mucosal application of 13c-pOVa leads 
to a Moderate induction of regulatory 
T cells and significantly Decreases the 
Frequency of effector T cells
To analyze whether transporter-mediated mucosal uptake of 
peptide induces a tolerogenic response as described for some 
oral immunization protocols [reviewed in Ref. (8)], we analyzed 
the expression of Foxp3, the master transcription factor of Tregs, 
as well as the cytokine expression of antigen-specific T cells that 
became activated upon mucosal application of the peptides.
Intrarectal administration of 13C-pOVA significantly 
increased frequencies of Foxp3+ cells 3 days after application 
which in the majority are also CD25+ (Figures  4A,B; Figure 
S4 in Supplementary Material). The increase was not due 
to enhanced deletion of non-Tregs since the frequency of 
antigen-specific cells remained unchanged compared to control 
animals (Figure S3 in Supplementary Material). Six days after 
intrarectal peptide application, frequencies of Foxp3+ Tregs 
were similar in pOVA and 13C-pOVA-treated animals (Figure 
S5F in Supplementary Material). Contrarily, after oral or nasal 
treatment, the increase in Foxp3 positive cells in the draining 
lymph nodes (MLN and MedLN, respectively) was small at day 
3 but increased until day 6 (Figures 5A,F; Figures S5A–D in 
Supplementary Material).
Animals treated with 13C-pOVA rectally exhibited higher 
frequencies of IL-10 producing T cells compared to treatment 
with pOVA (Figures  5D,I). As tolerance can also rely on the 
induction of anergy in antigen-specific cells, we measured the 
percentage of T cells producing the inflammatory cytokines TNF 
and IFNγ. Frequencies of TNF+ T cells appeared to be reduced 
upon mucosal application of 13C-pOVA (Figures  5B,G), but 
these differences were not statistically significant (p  =  0.23) 
due to high experimental variability. IFNγ-producing cells were 
generally very low in numbers and unchanged upon peptide 
treatment (Figures 5C,H). The calculation of the ratio of IL-10 
to TNF-producing cells in individual mice revealed a highly 
significant bias toward an anti-inflammatory cytokine milieu in 
13C-pOVA-treated animals (Figure 5E). We could not observe 
increased IL-10 frequency after oral treatment in MLN (Figure 
S6 in Supplementary Material). The IL-10 production in MedLN 
after nasal treatment could not be measured due to technical 
reasons.
In none of the mice we detected significant numbers of inter-
feron gamma (IFNγ)-producing T cells under the conditions 
used here. We conclude that the facilitated mucosal transport of 
peptide antigen increases the frequency of Foxp3+ Tregs. After 
FigUre 1 | coupling 13c to pOVa significantly enhances proliferation of antigen-specific cells upon mucosal application. Balb/c mice were injected 
with 5 × 106 CFSE-labeled CD4+ cells from DO11.10 donor mice. Twenty-four hours later, mice were treated mucosally with pOVA, 13C-pOVA, or phosphate-
buffered saline (PBS) as control. After 3 days, animals were sacrificed and the proliferation of pOVA-TCR+CD4+ T cells in different organs was analyzed by flow 
cytometry. (a) Representative histograms showing the CFSE dilution in the spleen after oral treatment with PBS, 0.5 mg (0.28 μmol) pOVA, or equimolar amounts of 
13C-pOVA. (B) T cell proliferation of mice, treated orally with 0.5 mg pOVA or equimolar amounts of 13C-pOVA. (c) Mice received 0.05 mg pOVA peptide or 
equimolar amounts of 13C-pOVA intranasally (nasal). (D) Mice were injected intrarectally with 0.5 mg pOVA peptide or equimolar amounts of 13C-pOVA. Pooled 
data from two to three individual experiments with the Geometric Mean are shown; symbols represent values from individual mice (n = 4–8). Statistical testing was 
performed for each individual organ using the non-parametric Mann–Whitney test and Holm–Bonferroni correction for multiple comparisons. The complete statistical 
results are shown in Table S1 in Supplementary Material. CLN, cervical lymph nodes; MLN, mesenteric lymph nodes; SLN, subcutaneous lymph nodes; MedLN, 
mediastinal lymph nodes.
5
Kenngott et al. Transmucosal Peptide Delivery and Tolerance
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 216
intrarectal treatment, the cytokine response was shifted toward 
the anti-inflammatory cytokine IL-10.
intrarectal Tolerization with 13c-pOVa 
reduces inflammation in a Model of DTh
To further investigate the tolerogenic potency of the 13C-pOVA 
peptide treatment, the peptide derivatives were tested in a DTH 
mouse model. Seven days after intrarectal peptide treatment, 
mice adoptively transferred with DO11.10 cells were injected 
subcutaneously with pOVA in CFA. Two weeks later, the 
footpad of the right hind leg was challenged by subcutaneous 
injection of pOVA in IFA and footpad swelling measured 24 h 
later. Animals pretreated intrarectally with 13C-pOVA peptide 
showed a significantly reduced footpad swelling, while DTH 
was not affected in mice pretreated with pOVA or 13Csc-pOVA 
(Figure 6). In addition, the frequency of pOVA-TCR+CD4+ cells 
in the draining popliteal lymph nodes was analyzed. The foot 
injected with pOVA/IFA emulsion showed significantly increased 
infiltration of antigen-specific CD4+ T cells compared to PBS, 
yet frequencies were not affected by the pretreatments (Figure 
S7 in Supplementary Material). Frequencies of IFNγ and IL-17-
producing cells were low among the cells and not changed by 
the treatment (Figure S8 in Supplementary Material). Additional 
data from oral and nasal vaccination experiments supported a 
FigUre 3 | 13c peptide is taken up by epithelial cells and cD11c-positive cells in the large intestine. Balb/c mice were anesthetized and injected with 
fluorescein isothiocyanate (FITC)-labeled peptides into a ligated loop of the large intestine. After 10 min, mice were sacrificed and the tissue fixed and frozen. 
Cryosectioned slides were stained with CD11c-Alexa647 (blue) and DAPI (gray) and analyzed by confocal microscopy. (a,D–F) Injection of 13C-FITC (green).  
(a) Lymphoid follicle in the large intestine. Overlay of DAPI, 13C-FITC, and CD11c staining. (D–F) Detail of image shown in [(a); red square]. (B,c) Injection of the 
control peptide 13Csc-FITC (green). (B) Lymphoid follicle in the large intestine. Overlay of DAPI, 13Csc-FITC and CD11c staining. (c) Overlay of 13Csc-FITC and 
CD11c staining. (D) As (a);  (e) CD11c staining; (F) 13C-FITC fluorescence. Pictures are representatives of three individual experiments with similar results. LP, 
lamina propria; L, lumen; gray, DAPI; blue, CD11c-Alexa647; green, FITC; scale in panels (a–c): 50 μm; scale in panels (D–F): 10 μm.
FigUre 2 | intrarectal treatment with 13c-pOVa peptide enhances 
proliferation of antigen-specific T cells. Balb/c mice were injected with 
5 × 106 CFSE-labeled CD4+ T cells from DO11.10 donor mice. Twenty-four 
hours later, mice were treated intrarectally with indicated amounts of pOVA 
peptide or equimolar amounts of 13Csc-pOVA or 13C-pOVA. After 3 days, 
animals were sacrificed and pOVA-TCR+CD4+ T cells in the mesenteric lymph 
nodes were analyzed by FACS. Pooled data from one to three individual 
experiments are shown (n = 4–8; Geo. mean ± SD). Statistical testing was 
performed for each time point using the non-parametric Kruskal–Wallis test.
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trend of reduced footpad swelling, increased frequencies of 
Tregs, and improved histopathology (Figure S9 in Supplementary 
Material). Taken together, these experiments demonstrated that 
mucosal pretreatment with pOVA coupled to the transporter 13C 
is inducing partial tolerance in this animal model.
DiscUssiOn
The gut environment features a number of different tolerogenic 
mechanisms, including high numbers of Tregs in the lamina 
propria that contribute to the tendency of mucosal immune 
reactions that result, in the absence of danger signals, in toler-
ance (9–11). For a long time, the induction of oral tolerance 
was seen as an attractive goal for therapeutic application, yet 
clinical trials have not been successful so far for several reasons 
(3). Intact proteins have mostly been used for vaccination, 
however, are difficult to standardize. In contrast, peptides are 
well-defined and more convenient regarding quality control. For 
both peptides and proteins, the gastrointestinal immunization 
route with its limited uptake efficiency and rapid degradation is 
a major obstacle.
The present study targets the issue of poor uptake of gastrointes-
tinal vaccines by application of a novel transmucosal transporter 
peptide that was previously found to carry cargo through the 
mucosal barrier. The 13C peptide, a nine amino acid long cyclic 
peptide facilitated mucosal uptake of coupled molecules by, as of 
yet, unknown mechanisms (4). We here studied the impact of this 
strategy on vaccination efficacy and tolerance induction in the 
DO11.10/OVA323-339 peptide (pOVA) model. Oral, rectal, and 
FigUre 4 | 13c-pOVa treatment slightly increases the frequency of 
regulatory T cells after intrarectal treatment. Mice were treated as 
described in Figure 1 and isolated cells from mesenteric lymph nodes were 
analyzed by flow cytometry on day 3 after peptide treatment for the 
expression of Forkhead-box-protein 3 (Foxp3). (a) Exemplary FACS dot plots 
of CFSE dilution and expression of Foxp3 among pOVA-TCR+CD4+ T cells. 
(B) Frequency of antigen-specific Foxp3+ T cells. Pooled data from six 
individual experiments; symbols represent values from individual mice 
(n = 9–12). Statistical testing was performed using One-way ANOVA 
(p = 0.0017) after confirming normality distribution using a D’Agostino and 
Pearson omnibus normality test (α = 0.05); statistical symbols represent 
results from Tukey’s multiple comparison post test.
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nasal application of 13C coupled to pOVA significantly increased 
in vivo proliferation of antigen-specific T cells compared to appli-
cation of pOVA in at least some lymphoid tissues. This indicates 
that 13C-pOVA is taken up via the mucosal surfaces more effi-
ciently than non-coupled pOVA, and functionally intact pOVA is 
delivered to and presented by APC. Consistent with the concept 
of shared properties of mucosal surfaces and a common mucosa-
associated lymphoid tissue, immunization via the oral, nasal, and 
rectal route all were able to activate the pOVA-specific T cells in 
draining and systemic lymphoid tissues, albeit with quantitative 
and qualitative differences. Nasal peptide application proved to 
be most efficient in inducing T cell proliferation. A superiority 
of the nasal route for T cell priming has also been observed for 
protein treatment (8, 12). However, in the DTH model studied 
here, an equal or better tolerogenic efficacy of nasal application 
could not be confirmed.
Microscopic analysis revealed that the fluorochrome-labeled 
13C transporter is taken up while the scrambled control peptide 
largely remains in the lumen of the large intestine, as already shown 
previously for the small intestine (4). Uptake is first observed in 
a subset of epithelial cells that have the morphological features of 
goblet cells, notably in the small intestine (4), but the conjugate 
also becomes detectable in mucosal CD11c+ cells, which mainly 
consist of DCs (Figure  3). The proportion of the conjugates 
remaining in DCs and the proportion being transported via lymph 
to the systemic circulation could not been determined with the 
present technique. However, the proliferation of antigen-specific 
cells on day 3 after treatment was comparable in all analyzed 
lymphoid tissues and was not restricted to the draining LN. This 
indicates that a major part of the transported peptide is delivered 
intact into circulation and not only presented on mucosal APC. It 
can be assumed that the increased proliferation of T cells in mice 
treated with 13C-pOVA is a consequence of a synergistic effect of 
faster delivery of the peptide itself throughout the body and direct 
uptake of the peptides by APC at the site of application. Whether 
or not migration of peptide-loaded DCs from the mucosa into the 
draining lymph node contributes to the systemic dissemination 
of T cell-activating potential, and whether or not a more rapid 
initial response can be observed at draining sites remains to be 
determined.
To our surprise we noticed that also some native pOVA was 
able to cross the mucosal surfaces and elicit T cell responses in 
mucosal as well as remote lymphoid tissues such as spleen or 
SLN. Thus, a small fraction of antigenic peptides might natu-
rally access the circulation in intact form; comparing the level 
of responses to peptide given by i.v. injection versus mucosal 
application, this fraction can be estimated to be less than 
1%. Nevertheless, coupling of pOVA to 13C peptide strongly 
improved the uptake.
It has been reported that feeding of ovalbumin protein in high 
doses leads to strong proliferation of the transferred antigen-
specific T cells; however, the cells become anergic or undergo 
activation induced cell death (AICD) (13–15). In contrast, low-
dose treatment with ovalbumin protein results in the induction 
of antigen-specific Tregs and, accordingly, this pathway has been 
seen as the predominant mechanism of low-dose tolerance (13, 
14). However, this view has been challenged by other work, 
showing that prolonged high-dose treatment can also increase 
the number of Foxp3+ Tregs (16).
The treatment with 0.25 mg (0.14 μmol) pOVA peptide used 
here is equivalent to approximately 6 mg ovalbumin protein, i.e., 
a rather low-dose range. Accordingly, a significant increase in 
the frequency of Foxp3+ Tregs compared to the non-immunized 
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animals was recorded, albeit the effect was not as pronounced 
as in other studies of oral immunization (16). However, despite 
strong T cell proliferation, indicated by loss of CFSE staining, the 
frequencies of transgenic T cells had only slightly increased at day 
3 (Figure S3 in Supplementary Material). Thus, a significant part 
of the proliferating cells appears to undergo AICD. While only 
FigUre 5 | changes in production of pro- and anti-inflammatory cytokines. Mice were treated as described in Figure 1 and isolated cells from mesenteric 
lymph nodes were analyzed by flow cytometry on day 6 for the expression of Forkhead-box-protein 3 (Foxp3) and various intracellular cytokines. (a,F) Foxp3 
frequency, (B,g) frequency of TNF producing, (c,h) frequency of IFNγ producing, and (D,i) frequency of IL-10-producing pOVA-TCR+CD4+ T cells. (e) Ratio of T cells 
expressing IL-10 and TNF. (a–e) Pooled data from two to three individual experiments are shown; symbols represent values from individual mice (n = 5–8). Statistical 
testing was performed using the non-parametric Mann–Whitney test and Holm–Bonferroni correction for multiple comparisons. (F–i) Representative dot plots.
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FigUre 6 | reduced footpad swelling in delayed-type hypersensitivity 
after tolerization with 13c-pOVa peptide. Balb/c mice were injected with 
5 × 106 CFSE-labeled CD4+ cells from DO11.10 donor mice. Twenty-four 
hours later, the mice were tolerized intrarectally with 0.25 mg (0.14 μmol) of 
pOVA or equimolar amounts of 13C-pOVA or 13Csc-pOVA or phosphate-
buffered saline (PBS) as control. On day 8, the mice were immunized by 
tail-base injection of pOVA/CFA emulsion. On day 22, the mice were injected 
with pOVA/IFA emulsion into the right footpad (the left footpad received PBS/
IFA as control). The following day, footpad swelling was measured. The graph 
shows the footpad swelling of the IFA/pOVA injected foot compared to the 
control foot. Pooled data from three individual experiments are shown; 
symbols represent values from individual mice (n = 13–15). Statistical testing 
was performed using One-way ANOVA (p = 0.0082) after confirming 
normality distribution via D’Agostino and Pearson omnibus test (α = 0.05); 
statistical symbols in graph represent result from Tukey’s multiple 
comparisons post test.
a minor, non-significant reduction in TNF-producing effector 
cells was observed upon immunization with peptides, 13C-pOVA 
induced an increase in IL-10 producing T cells and hence in the 
ratio IL-10/TNF, suggesting that the peptide immunization via 
the mucosal route increased IL-10-mediated regulatory pathways.
Both IL-10 producing T cells (“TR1”) and Foxp3+, Tregs have 
been implicated in the suppression of inflammation in DTH or 
other models (17, 18). Indeed, in a DTH model, mucosal applica-
tion of 13C-pOVA, but not pOVA, resulted in a significant, yet 
only partial suppression of footpad swelling upon rectal vaccina-
tion, and a trend to reduced inflammation upon oral and nasal 
vaccination (Figure S9 in Supplementary Material). Mucosal 
vaccination with 13C-pOVA in this model resulted consistently in 
increased frequencies of Tregs, while the effects on cytokines were 
less clear after immunization and challenge. A definite analysis of 
the pathways causing the partial suppression of the DTH requires 
blocking/deletion experiments, which was beyond the scope of 
the present study. In previous studies, tolerization in the DTH 
model was achieved by feeding high doses of ovalbumin protein 
(18). At the peptide dose applied here, only pOVA coupled to 13C 
was able to significantly modulate the DTH response. Using this 
model of a strongly inflammatory disease, it can be concluded that 
the enhanced uptake of the transporter-coupled antigenic peptide 
led to more vigorous T cell proliferation, without increased effec-
tor cell frequencies, and some increase in antigen-specific Tregs. 
However, it has to be emphasized that the delivery of antigenic 
peptide by the mucosal route by itself is not as effective in inducing 
a robust tolerance as might have been expected. Whether this can 
be improved by altering conditions (e.g., repeated vaccination) 
and whether a clear preference for one of the mucosal application 
routes can be secured, remains to be shown.
We have previously demonstrated that the 13C peptide is also 
able to carry large proteins in intact form through the mucosal 
barrier (4). It will be interesting to test whether tolerization with 
intact proteins using this targeting pathway leads to different 
results compared with high-dose oral protein application, where 
most likely only peptides reach the circulation. The ability to 
deliver macromolecules via the mucosal barrier by virtue of the 
13C peptide also provides novel opportunities of combining anti-
gens with either tolerogenic or immunogenic adjuvant compo-
nents, e.g., by coupling additionally either immunosuppressive or 
stimulatory cytokines to the antigen-transporter complex. Thus, 
the carrier peptide 13C might become a valuable component in 
a toolbox of functional units to be used for engineering novel 
immunomodulatory agents.
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